News

Press Releases

May 17, 2023

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

May 2, 2023

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

October 21, 2022

ELIXIR MEDICAL EXPANDS LEADERSHIP TEAM WITH ADDITION OF ALEXEY NEPOGODIEV AS EXECUTIVE VICE PRESIDENT, GLOBAL MARKETING

1 2 3 4 ›»

May 17, 2023

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

May 2, 2023

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

October 21, 2022

ELIXIR MEDICAL EXPANDS LEADERSHIP TEAM WITH ADDITION OF ALEXEY NEPOGODIEV AS EXECUTIVE VICE PRESIDENT, GLOBAL MARKETING

1 2 3 4 ›»

Media Coverage

April 2021

Medtech Insight

Start-Up Spotlight: Elixir Works to ‘Uncage’ The Coronary After Intervention

June 2020

TCTMD/The Heartbeat

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

Cardiovascular News

PCR e-Course 2020: DynamX Bioadaptor shows “excellent” safety and efficacy at 12 months

Media Resources

Media contact:

Email to PR@ElixirMedical.com

DynamX transparent

3300 px x 875 px
PNG

DynamX Blue Background

3840 px x 2160 px
PNG

DynamX Alone

1920 x 1080
MP4

DynamX In Vessel

1920 x 1080
MP4

News

Press Releases

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

ELIXIR MEDICAL EXPANDS LEADERSHIP TEAM WITH ADDITION OF ALEXEY NEPOGODIEV AS EXECUTIVE VICE PRESIDENT, GLOBAL MARKETING

EUROPCR 2023: LATE-BREAKING CLINICAL DATA DEMONSTRATE ELIXIR MEDICAL’S DYNAMX BIOADAPTOR RESTORES VESSEL MOTION AND FUNCTION WITH BETTER EFFECTIVENESS AT 12 MONTHS COMPARED TO A LEADING DRUG-ELUTING STENT (DES)

ELIXIR MEDICAL TO ANNOUNCE LATE-BREAKING CLINICAL DATA AT EUROPCR 2023 SESSION FEATURING WORLD’S FIRST TRANSFORMING CORONARY ARTERY IMPLANT DESIGNED TO RESTORE VESSEL PHYSIOLOGY AND FUNCTION

ELIXIR MEDICAL EXPANDS LEADERSHIP TEAM WITH ADDITION OF ALEXEY NEPOGODIEV AS EXECUTIVE VICE PRESIDENT, GLOBAL MARKETING

Media Coverage

April 2021

Medtech Insight

June 2020

TCTMD/The Heartbeat

Cardiovascular News

Media Resources

Media contact:

DynamX transparent

DynamX Blue Background

DynamX Alone

DynamX In Vessel

PMN 574 Rev A

Elixir, Innovation for Life and DESyne are registered trademarks, and DynamX a trademark, in the US and internationally for Elixir Medical Corporation.

DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting Coronary Stent System are CE Mark approved.

©2022 Elixir Medical. All rights reserved.

Site designed by The Deciding Factor, Inc.